A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

NCT06939452 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Interventions

DRUG: anlotinib +TQB2450 + Oxaliplatin+S-1

Sponsor

Yongxu Jia